Clinical Trial: A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma

U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT07520357) titled 'A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma' on April 03.

Brief Summary: This is a prospective, single-center, phase II trial designed to evaluate the efficacy and safety of SHR-A1904 monotherapy in second-line or later treatment of advanced neuroendocrine carcinoma. The primary endpoint is the objective response rate. Secondary endpoints include progression free survival, overall survival rate, duration of response, disease control Rate and adverse event.

Study Start Date: April 30

Study Type: INTERVENTIONAL

Condition: Advanced Neuroendocrine Carcino...